iRegene

Wuhan, China · Founded 2017 · Privately Held (backing)

Developer of chemically-derived allogeneic cell therapies aims to provide first-in-class treatments for major degenerative diseases. iRegene is based in Wuhan, China and was founded in 2017. Its last reported valuation was $569 million in Apr 2025. It has raised $393 million.

Last reported valuation
$568.6M
Oct 2026
Priced at
—
Total raised
$392.8M
Last round
—

Who backs iRegene?

14 investors
InvestorType
Northern Light Venture CapitalOther
Vertex Ventures ChinaVenture capital
GSR United CapitalVenture capital
Orinno CapitalOther
Lotus Lake VenturesVenture capital
Optics Valley Industry InvestmentGrowth equity
Chengdu Bio-Town InvestmentOther
Holley GroupOther
CEC Capital Group—
Changjiang Securities Company—
+ 4 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

iRegene investors

14 investors are on record for iRegene, including Northern Light Venture Capital, Vertex Ventures China, GSR United Capital and Orinno Capital.

Free account
More of iRegene with a free account
  • ·The complete investor list: 14 names
  • ·Watch iRegene: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 14 firms already write checks for companies like iRegene. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View